Placeholder Banner

Cell and Gene Therapy

Cell and gene therapy (CGT) products have the potential to cure intractable diseases, bring hope and meaningful benefit to patients in need, and change the way we approach treating disease.  These therapies often target rare diseases and conditions, where patients often have limited treatment options.  As the CGT product development cycle presents unique challenges and opportunities, BIO is engaging in regulatory advocacy efforts across the product lifecycle.  Here you will find BIO consensus documents describing policy positions on a variety of topics, from nonclinical to manufacturing and clinical phases. 

bg-1
Comparability

This BIO short consensus document describes points to consider regarding comparability for CGT products and was developed by BIO’s Cell and Gene Therapy Manufacturing, Quality and Distribution Task Force.

bg_4_resized
Potency

This BIO short consensus document describes points to consider regarding potency for CGT products and was developed by BIO’s Cell and Gene Therapy Manufacturing, Quality and Distribution Task Force.

Check Out Our Latest Webinar:

Gene-editing webinar title card

The Cell and Gene Therapy (CGT) Science Series is a quarterly seminar series focused on scientific topics related to cell and gene therapy products. The CGT Science Series is intended to foster scientific exchange between the Biotechnology Innovation Organization (BIO), the American Society of Cell & Gene Therapy (ASGCT), and Center for Biologics Evaluation and Research (CBER) review staff on a variety of topics that span the CGT product lifecycle. The seminars are planned as 60-minute virtual webinars featuring a speaker from one of the three organizations. The CGT Science Series will enable a deep dive into a specific technical and/or scientific area. Topics in the series may include but are not limited to, nonclinical, CMC, clinical, or post-market phases of development related to CGT product lifecycle.

Moderator:
– Anne-Virginie Eggimann, Tessera

Opening Remarks:
– Cartier Esham, Chief Scientific Officer, Biotechnology Innovation Organization (BIO)

Speaker:
– Jing Liao, Director, Vector Development and Operations, Alexion Pharmaceuticals

BIO Comment Letters

Here is a listing of BIO’s most recent comments submitted to health authorities related to regulation of CGT products: